US · ANIK
Anika Therapeutics, Inc.
- Sector
- Healthcare · Medical - Devices
- Headquarters
- Bedford, MA 01730
- Website
- anikatherapeutics.com
Price · as of 2025-12-31
$14.85
Market cap 207.09M
Valuation summary
Four models, one snapshot. Upside is target ÷ current − 1.
| Valuation method | Value, $ | Upside, % |
|---|---|---|
| Artificial Intelligence(AI) | $36.89 | +148.42% |
| Intrinsic Value(DCF) | $6.75 | -54.55% |
| Graham-Dodd Method(GD) | $5.65 | -61.95% |
| Graham Formula(GF) | — | — |
Valuation history
Annual price (USD per share) overlaid with each model's fair value. Y-axis is log scale.
| Year | Price | AI | DCF | Graham-Dodd | Graham Formula |
|---|---|---|---|---|---|
| 2011 | $11.90 | $40.29 | $80.38 | $9.81 | $15.56 |
| 2012 | $14.09 | $56.20 | $55.45 | $11.96 | $15.86 |
| 2013 | $42.15 | $67.93 | $18.48 | $16.26 | $19.14 |
| 2014 | $39.75 | $69.30 | $28.76 | $24.62 | $122.61 |
| 2015 | $44.62 | $77.50 | $14.58 | $23.92 | $0.00 |
| 2016 | $44.59 | $109.00 | $12.46 | $25.77 | $41.77 |
| 2017 | $53.49 | $73.70 | $15.10 | $28.43 | $38.21 |
| 2018 | $30.66 | $71.39 | $9.26 | $24.19 | $1.86 |
| 2019 | $41.41 | $70.69 | $14.06 | $29.51 | $31.50 |
| 2020 | $37.07 | $106.11 | $1.76 | $10.13 | $0.00 |
| 2021 | $25.58 | $83.13 | $0.00 | $20.83 | $5.96 |
| 2022 | $26.10 | $120.80 | $0.84 | $14.01 | $14.15 |
| 2023 | $25.42 | $145.13 | $0.00 | $0.00 | $0.00 |
| 2024 | $16.62 | $422.93 | $0.00 | $0.00 | $0.00 |
| 2025 | $14.32 | $36.89 | $0.00 | $5.65 | $0.00 |
AI valuation
Our deep-learning model estimates Anika Therapeutics, Inc.'s (ANIK) per-share fair value from quarterly fundamentals, sector trend, and historical valuation patterns.
- AI fair value
- $36.89
- Current price
- $14.85
- AI upside
- +148.42%
Methodology and confidence bands appear in the dedicated valuation theory section. The AI score is an estimate, not a recommendation.
Intrinsic value (DCF)
Open DCF calculatorThree textbook valuation models, recomputed daily from the latest financial statements. The DCF uses our Chepakovich model. Graham-Dodd and Graham Formula are conservative reference points.
DCF
$6.75
-54.55% upside
Graham-Dodd
$5.65
-61.95% upside
Graham Formula
—
— upside
Peer comparison
Same-industry comparables, ranked by market cap.
| Basic Info | Model Valuation | Core Valuation | Profitability | Leverage & Liquidity | Growth | Cash Flow | Dividends | Enterprise Value | Risk | ||||||||||||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Ticker | Company Name | Price | Market Cap | AI Upside | DCF Upside | GD Upside | GF Upside | P/E | P/B | P/S | EV/EBITDA | PEG | P/TBV | Gross Margin | Operating Margin | Net Margin | ROE | ROIC | ROA | Debt/Equity | Interest Coverage | Current Ratio | Quick Ratio | Net Debt/EBITDA | EPS Growth | Sales Growth | FCF Growth | FCF Yield | Op Cash Flow Ratio | Cash ROIC | Dividend Yield | Dividend Payout | Shareholder Yield | EV/EBIT | EV/FCF | EV/Sales | Altman Z-Score |
| ANIK | Anika Therapeutics, Inc. | $14.85 | 207.09M | +148% | -55% | -62% | — | -18.87 | 1.43 | 1.82 | -93.81 | — | 1.54 | 56.56% | -9.80% | -9.64% | -7.32% | -9.43% | -5.54% | 0.17 | -6.34 | 4.72 | 3.71 | 18.15 | -8016.00% | -591.00% | -28713.00% | 2.12% | 0.51 | 3.72% | 0.00% | 0.00% | 6.37% | -15.57 | 39.44 | 1.53 | 3.99 |
| ANIX | Anixa Biosciences, Inc. | $2.98 | 99.47M | — | — | — | — | -9.95 | 7.24 | — | -8.10 | — | 7.24 | 0.00% | — | — | -62.73% | -4708.65% | -58.55% | 0.01 | — | 8.08 | 7.71 | 0.09 | -1282.00% | — | -221.00% | -6.54% | -3.65 | -2886.52% | 0.00% | 0.00% | 0.00% | -8.10 | -13.21 | — | 7.63 |
| APYX | Apyx Medical Corporation | $3.27 | 134.17M | +662% | -86% | — | — | -1.69 | 2.80 | 0.83 | -2.79 | -7.60 | 2.80 | 61.04% | -39.18% | -48.78% | -115.17% | -88.10% | -32.70% | 2.73 | -3.19 | 5.26 | 4.40 | -0.42 | 2222.00% | -811.00% | 22461.00% | -47.15% | -1.68 | -87.74% | 0.00% | 0.00% | 0.00% | -2.49 | -2.50 | 0.97 | -0.58 |
| ARAY | Accuray Incorporated | $0.58 | 68.6M | +5,263% | +4% | -74% | — | -97.54 | 1.91 | 0.34 | 13.55 | — | 6.65 | 32.05% | 1.71% | -0.35% | -2.52% | 1.62% | -0.34% | 2.17 | 0.61 | 1.65 | 0.81 | 5.88 | -9031.00% | 268.00% | -6348.00% | -3.65% | 0.01 | -2.92% | 0.00% | 0.00% | 14.96% | 34.97 | -48.41 | 0.60 | 0.04 |
| AVR | Anteris Technologies Glob… | $6.51 | 239.49M | +229% | -58% | — | +1,116% | -1.66 | -1678.27 | 81.59 | -1.58 | -27.15 | -987.84 | 70.26% | 24.41% | -4925.51% | -300.71% | -5.60% | -181.73% | -24.54 | 6.40 | 0.73 | 0.59 | 0.11 | 610.00% | -2923.00% | 2251.00% | -49.85% | -3.64 | 932.39% | 0.00% | 0.00% | 0.00% | 312.17 | -1.87 | 76.21 | -18.68 |
| LNSR | LENSAR, Inc. | $11.97 | 142.98M | +705% | -42% | — | — | -5.45 | 9.18 | 3.20 | -50.35 | -5.03 | 13.66 | 48.33% | -19.94% | -58.71% | -95.42% | -88.05% | -46.22% | 0.14 | — | 2.80 | 1.93 | 4.54 | 10840.00% | 2687.00% | -7543.00% | -1.42% | -0.15 | -20.07% | 0.00% | 0.00% | 0.00% | -14.19 | -62.24 | 2.83 | -0.11 |
| LUCD | Lucid Diagnostics Inc. | $1.44 | 146.54M | +85,309% | -60% | — | — | -1.54 | 13.02 | 16.16 | -1.56 | — | 15.08 | -90.20% | -1059.64% | -1047.61% | -2956.43% | 5531.77% | -157.04% | 3.94 | -1771.23 | 1.07 | 0.97 | 0.02 | -1667.00% | 7900.00% | 3556.00% | -63.78% | -1.88 | 5379.70% | 0.00% | 0.00% | 0.00% | -1.50 | -1.54 | 15.90 | -12.37 |
| MXCT | MaxCyte, Inc. | $0.81 | 86.54M | +3,073% | +164% | -99% | — | -8.96 | 1.78 | 9.53 | -4.99 | -165.84 | 1.78 | 81.62% | -132.54% | -106.29% | -18.73% | -67.18% | -16.17% | 0.09 | — | 10.88 | 10.09 | 0.21 | 541.00% | -644.00% | 1526.00% | -7.95% | -1.75 | -38.39% | 0.00% | 0.00% | 0.00% | -4.52 | -7.91 | 6.00 | 5.62 |
| OWLT | Owlet, Inc. | $11.55 | 184.81M | +401% | +393% | — | — | -5.81 | -3.44 | 0.93 | -6.80 | — | -3.29 | 50.36% | -25.90% | -16.06% | 49.33% | 68.11% | -26.78% | -0.56 | -12.40 | 1.27 | 0.89 | 0.88 | -8168.00% | 4452.00% | -4925.00% | -16.44% | -0.31 | 40.32% | 0.00% | 0.00% | 11.27% | -3.19 | -5.38 | 0.83 | -6.50 |
| QIPT | Quipt Home Medical Corp. | $3.63 | 161.41M | +679% | +41,027% | -84% | — | -9.83 | 0.75 | 0.31 | 5.02 | -17.48 | 183.07 | 70.09% | -1.56% | -3.13% | -8.67% | -2.44% | -3.34% | 0.85 | -0.79 | 1.46 | 0.64 | 2.52 | 5625.00% | 3883.00% | 108.00% | 24.09% | 0.50 | 11.61% | 0.00% | 0.00% | 0.12% | -39.68 | 8.33 | 0.62 | 0.40 |
| RPID | Rapid Micro Biosystems, I… | $4.33 | 191.92M | +463% | -78% | — | — | -2.22 | 1.38 | 3.71 | -1.28 | — | 1.38 | -0.39% | -177.96% | -167.16% | -48.50% | -155.83% | -38.81% | 0.08 | — | 4.61 | 3.32 | 0.23 | -1148.00% | 2457.00% | -300.00% | -43.71% | -2.51 | -142.09% | 0.00% | 0.00% | 0.00% | -1.19 | -1.31 | 2.12 | -4.66 |
About Anika Therapeutics, Inc.
Anika Therapeutics, Inc., a joint preservation company, creates and delivers advancements in early intervention orthopedic care in the areas of osteoarthritis (OA) pain management, regenerative solutions, soft tissue repair, and bone preserving joint technologies in the United States, Europe, and internationally. The company develops, manufactures, and commercializes products based on hyaluronic acid (HA) technology platform. Its OA pain management product family consists of Monovisc, Orthovisc, Cingal, and Hyvisc that are indicated to provide pain relief from osteoarthritis conditions; and joint preservation and restoration product family comprise a portfolio of approximately 150 bone preserving joint technology products, a line of sports medicine soft tissue repair solutions, and orthopedic regenerative solutions products. The company's non-orthopedic product family include HA-based products for non-orthopedic applications, including adhesion barrier products, advanced wound care products, ophthalmic products, and ear, nose, and throat products. Anika Therapeutics, Inc. was founded in 1983 and is headquartered in Bedford, Massachusetts.
- CEO
- Stephen D. Griffin
- Employees
- 288
- Beta
- 0.43
Disclaimer: Information on this page is provided for educational purposes only and does not constitute investment advice. Upside computed as ($6.75 ÷ $14.85) − 1 = -54.55% (DCF, example).